Journal: Frontiers in Pharmacology
Article Title: Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis
doi: 10.3389/fphar.2022.938134
Figure Lengend Snippet: FDX1 is downregulated by elesclomol, resulting in inhibiting cell viability in BLCA, ccRCC, and PCa. (A,F,K) The expression level of FDX1 was evaluated in BLCA, ccRCC, and PCa cells and their corresponding normal cells by qRT-PCR and western blot. (B,G,L) The expression level of FDX1 in BLCA, ccRCC, and PCa cell lines treated with elesclomol after 16 h. (E,J,O) The fold Caspase 3/7 activity in BLCA, ccRCC, and PCa cell lines after treated with elesclomol after 16 h. (C,D,H,I,M,N) The cell viability of BLCA, ccRCC, and PCa cell lines after treatment with elesclomol.
Article Snippet: The immortalized normal human urothelial cell line SV-HUC-1 and human bladder urothelial carcinoma (BLCA) cell lines T24 and 5637, and human proximal tubular epithelial cell line HK-2 and human clear cell renal cell carcinoma (ccRCC) cell lines 786-O and caki-1, and human normal prostatic epithelial cells RWPE-1 and human prostate cancer (PCa) cell lines PC-3 and DU145 were all purchased from Procell Life Science and Technology Co., Ltd. (Wuhan, China).
Techniques: Expressing, Quantitative RT-PCR, Western Blot, Activity Assay